

12-20-06

JFW

PTO/SB/21 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

5

Application Number

10/693,315-Conf. #1495

Filing Date

October 24, 2003

First Named Inventor

Takao Abe

Art Unit

1624

Examiner Name

M. L. Berch

Attorney Docket Number

0036119.00227US1/AM100905

**ENCLOSURES (Check all that apply)**☒ Fee Transmittal Form☐ Fee Attached☐ Amendment/Reply☐ After Final☐ Affidavits/declaration(s)☐ Extension of Time Request☐ Express Abandonment Request☒ Information Disclosure Statement☐ Certified Copy of Priority Document(s)☐ Reply to Missing Parts/  
Incomplete Application☐ Reply to Missing Parts under  
37 CFR 1.52 or 1.53☐ Drawing(s)☐ Licensing-related Papers☐ Petition☐ Petition to Convert to a  
Provisional Application☐ Power of Attorney, Revocation  
Change of Correspondence Address☐ Terminal Disclaimer☐ Request for Refund☐ CD. Number of CD(s) \_\_\_\_\_☐ Landscape Table on CD☐ After Allowance Communication  
to TC☐ Appeal Communication to Board of  
Appeals and Interferences☐ Appeal Communication to TC  
(Appeal Notice, Brief, Reply Brief)☐ Proprietary Information☐ Status Letter☒ Other Enclosure(s) (please  
Identify below).

Return Receipt Postcard

Remark:

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name

WILMER CUTLER PICKERING HALE AND DORR LLP

Signature

Printed name

Colleen Superko

Date

December 19, 2006

Reg. No.

39,850

Express Mail Label No. EV933492744US Dated: December 19, 2006



PTO/SB/17 (07-06)  
Approved for use through 01/31/2007. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

<b>FEE TRANSMITTAL</b> <b>For FY 2006</b>		<b>Complete if Known</b>	
		Application Number	10/693,315-Conf. #1495
		Filing Date	October 24, 2003
		First Named Inventor	Takao Abe
		Examiner Name	M. L. Berch
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27	Art Unit	1624	
<b>TOTAL AMOUNT OF PAYMENT</b>	<b>(\$)</b> 180.00	Attorney Docket No.	0036119.00227US1/AM100905


<b>METHOD OF PAYMENT</b> (check all that apply)	
<input type="checkbox"/> Check	<input type="checkbox"/> Credit Card
<input type="checkbox"/> Money Order	<input type="checkbox"/> None
<input type="checkbox"/> Other (please identify): _____	
<input checked="" type="checkbox"/> Deposit Account	Deposit Account Number: 08-0219
Deposit Account Name: Wilmer Cutler Pickering Hale and Dorr LLP	
For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)	
<input checked="" type="checkbox"/> Charge fee(s) indicated below	<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee
<input checked="" type="checkbox"/> Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17	<input checked="" type="checkbox"/> Credit any overpayments

<b>FEE CALCULATION</b>							
<b>1. BASIC FILING, SEARCH, AND EXAMINATION FEES</b>							
	<b>FILING FEES</b>		<b>SEARCH FEES</b>		<b>EXAMINATION FEES</b>		
		<b>Small Entity</b>		<b>Small Entity</b>		<b>Small Entity</b>	
<b>Application Type</b>	<b>Fee (\$)</b>	<b>Fee (\$)</b>	<b>Fee (\$)</b>	<b>Fee (\$)</b>	<b>Fee (\$)</b>	<b>Fee (\$)</b>	<b>Fees Paid (\$)</b>
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	
<b>2. EXCESS CLAIM FEES</b>							
						<b>Fee (\$)</b>	<b>Small Entity Fee (\$)</b>
<b>Fee Description</b>							
Each claim over 20 (including Reissues)						50	25
Each independent claim over 3 (including Reissues)						200	100
Multiple dependent claims						360	180
<b>Total Claims</b>		<b>Extra Claims</b>	<b>Fee (\$)</b>	<b>Fee Paid (\$)</b>	<b>Multiple Dependent Claims</b>		
_____ - 20 = _____		x _____	= _____		<b>Fee (\$)</b>	<b>Fee Paid (\$)</b>	
HP = highest number of total claims paid for, if greater than 20.							
<b>Indep. Claims</b>		<b>Extra Claims</b>	<b>Fee (\$)</b>	<b>Fee Paid (\$)</b>			
_____ - 3 = _____		x _____	= _____				
HP = highest number of independent claims paid for, if greater than 3.							
<b>3. APPLICATION SIZE FEE</b>							
If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).							
<b>Total Sheets</b>	<b>Extra Sheets</b>	<b>Number of each additional 50 or fraction thereof</b>	<b>Fee (\$)</b>	<b>Fee Paid (\$)</b>			
_____ - 100 = _____	/50	_____ (round up to a whole number) x _____	= _____				
<b>4. OTHER FEE(S)</b>							
Non-English Specification, \$130 fee (no small entity discount)							
Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement						180.00	

<b>SUBMITTED BY</b>			
Signature	<i>Colleen Superko</i>	Registration No. (Attorney/Agent)	39,850
Name (Print/Type)	Colleen Superko	Telephone	(617) 526-6000
		Date	December 19, 2006

Express Mail Label No. EV933492744US	Dated: December 19, 2006
--------------------------------------	--------------------------

Docket No.: 0036119.00227US1/AM100905  
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Takao Abe Confirmation No.: 1495  
Application No.: 10/693,315 Art Unit: 1624  
Filed: October 24, 2003 Examiner: M. L. Berch  
Title: PROCESS FOR PREPARING 6-ALKYLIDENE PENEM DERIVATIVES

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.97 and 1.98, Applicants bring to the attention of the Examiner the documents listed on the attached Form SB/08.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97 (c) (2), after the mailing of a Final Office Action on the merits. Pursuant to 37 C.F.R. § 1.97 (c)(2), the \$180.00 fee should be charged to Deposit Account No. 08-0219.


Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB/08 with the next communication.

Respectfully submitted,

Dated: December 19, 2006

Colleen Superko  
Registration No.: 39,850  
Attorney for Applicant(s)

Wilmer Cutler Pickering Hale and Dorr LLP  
60 State Street  
Boston, Massachusetts 02109  
(617) 526-6000 (telephone)  
(617) 526-5000 (facsimile)



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	2	Attorney Docket Number	0036119.00200US3
-------	---	----	---	------------------------	------------------

**Complete if Known**

Application Number	11/283,288-Conf. #4075
Filing Date	November 18, 2005
First Named Inventor	Aranapakam M. Venkatesan
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	0036119.00200US3

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA*	US-20030080312-A1	08-10-2004	Seddon et al.	
	AB*	US-20040043978	03-01-2004	Venkatesan et al.	
	AC*	US-20050101654-A1	09-26-2006	Weiberth et al.	
	AD*	US-4,206,067	06-03-1980	MacKinnon	
	AE*	US-4,891,369	01-02-1990	Torii et al.	
	AF*	US-6,268,393	07-31-2001	Xu et al.	
	AG*	US-7,018,997-A1	03-28-2006	Venkatesan et al.	
	AH*	US-7,112,582-A1	09-26-2006	Venkatesan et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BA	EP-0167050	01-08-1986	Beecham Group Plc		
	BB	WO-03/093277	11-13-2003	Wyeth Corp et al.		
	BC	WO-03/093279	11-13-2003	Wyeth Corp et al.		
	BD	WO-03/093280	11-13-2003	Wyeth Corp et al.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	BUSH, "β-Lactamases of Increasing Clinical Importance", Cur. Pharm. Design, 5:839-845 (1999)	
	CB	BUSH, et al., "Kinetic Interactions of Tazobactam with β-Lactamases from All Major Structural Classes", Antimicrobial Agents and Chemotherapy, 37(4):851-858(1993)	
	CC	CIGNARELLA, et al., "6-Chloro- and 6-Bromopenicillanic Acids", J. Org. Chem., 27:2668-2669 (1962)	
	CD	COLEMAN, "Anti-Infectives: An Update on β-Lactamases and β-Lactamase Inhibitors", Expert Opin. Invest. Drugs, 4(8):693-704 (1995)	
	CE	Grant and Hackh's Chemical Dictionary, Fifth Edition, page 412 (1987)	
	CF	HASLAM, "Protection of Carboxyl Groups", Protective Groups in Organic Chemistry, Chapter 5, McOmie, ed., Plenum Press, pg. 183-215 (1973)	
	CG	JONES, "Resistance Patterns Among Nosocomial Pathogens: Trends Over the Past Few Years", Chest, 119:397S-404S (2001)	
	CH	OSBORNE, et al., "A Novel and Stereocontrolled Synthesis of (5R)-(Z)-6-(1-Methyl-1,2,3-Triazol-4-Ylmethylene)Penem-3-Carboxylic Acid, A Potent Broad Spectrum β-Lactamase	

Examiner Signature	Date Considered
-----------------------	--------------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	11/283,288-Conf. #4075
				Filing Date	November 18, 2005
				First Named Inventor	Aranapakam M. Venkatesan
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	0036119.00200US3

		Inhibitor", Journal of The Chemical Society, Letchworth, Great Britain, 6:371-373 (1989)	
	CI	PAYNE, et al., "β-Lactamase Epidemiology and the Utility of Established and Novel β-Lactamase Inhibitors", Exp. Opin. Invest. Drugs, 9(2):247-261 (2000)	
	CJ	RIETSCHA, et al., "Collaborative Clinical Pharmacokinetics Service in a Community Hospital", Am. J. Hosp. Pharm., 41:463-477 (1984)	
	CK	SANDERS, "Cefepime: The Next Generation?", Clin. Infect. Dis., 17:369-379 (1993)	
	CL	SUTHERLAND, "β-Lactam/β-Lactamase Inhibitor Combinations: Development, Antibacterial Activity and Clinical Applications", Infection, 23(4):191-200 (1995)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--